204 related articles for article (PubMed ID: 27023842)
1. [Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG)].
Bittner S; Meuth SG
Nervenarzt; 2016 Apr; 87(4):394-401. PubMed ID: 27023842
[TBL] [Abstract][Full Text] [Related]
2. [Effect of the German Act on the reform of the market for medicinal products (AMNOG) on the quality of neurological and psychiatric treatment].
Hamer H; Meyer-Lindenberg A
Nervenarzt; 2016 Apr; 87(4):351-2. PubMed ID: 27025218
[No Abstract] [Full Text] [Related]
3. [Requirements for drug approval and additional benefits assessment: Regulatory aspects and experiences].
Broich K; Löbker W; Schulte A; Beinlich P; Müller T
Nervenarzt; 2016 Apr; 87(4):376-85. PubMed ID: 27003322
[TBL] [Abstract][Full Text] [Related]
4. [The new German drug market law AMNOG from a child and adolescent psychiatry perspective].
Dittmann RW
Nervenarzt; 2016 Apr; 87(4):367-75. PubMed ID: 26992908
[TBL] [Abstract][Full Text] [Related]
5. [Impact of early benefit assessment on patients with epilepsy in Germany: Current healthcare provision and therapeutic needs].
Strzelczyk A; Hamer HM
Nervenarzt; 2016 Apr; 87(4):386-93. PubMed ID: 26927680
[TBL] [Abstract][Full Text] [Related]
6. [Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy].
Gründer G
Nervenarzt; 2016 Apr; 87(4):356-66. PubMed ID: 26983820
[TBL] [Abstract][Full Text] [Related]
7. [Earlier value assessment of pharmaceutical products and medical science].
Selbmann HK
Nervenarzt; 2016 Apr; 87(4):353-5. PubMed ID: 27000270
[No Abstract] [Full Text] [Related]
8. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
Fischer KE; Stargardt T
Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
[TBL] [Abstract][Full Text] [Related]
9. 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
Büssgen M; Stargardt T
Appl Health Econ Health Policy; 2023 Sep; 21(5):751-759. PubMed ID: 37249741
[TBL] [Abstract][Full Text] [Related]
10. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal products.
Schwander B; Banz K; Kaier K; Walzer S
Health Policy; 2014 Sep; 117(3):334-44. PubMed ID: 25059744
[TBL] [Abstract][Full Text] [Related]
12. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
Hörn H; Nink K; McGauran N; Wieseler B
Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
[TBL] [Abstract][Full Text] [Related]
13. Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: A study based on federal joint committee data.
Peinemann F; Labeit A
J Evid Based Med; 2019 Feb; 12(1):9-15. PubMed ID: 30701688
[TBL] [Abstract][Full Text] [Related]
14. [The AMNOG and its consequences].
Dingermann T
Internist (Berl); 2013 Jun; 54(6):769-74. PubMed ID: 23475259
[TBL] [Abstract][Full Text] [Related]
15. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
[TBL] [Abstract][Full Text] [Related]
16. [Drug assessment: IQWiG, G-BA, and an international comparison].
Glaeske G
Internist (Berl); 2016 Jan; 57(1):94-101. PubMed ID: 26502888
[TBL] [Abstract][Full Text] [Related]
17. Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
Blome C; Augustin M; Metin H; Lohrberg D
Eur J Health Econ; 2017 Mar; 18(2):181-193. PubMed ID: 26837412
[TBL] [Abstract][Full Text] [Related]
18. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
19. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
Ruof J; Schwartz FW; Schulenburg JM; Dintsios CM
Eur J Health Econ; 2014 Jul; 15(6):577-89. PubMed ID: 23771769
[TBL] [Abstract][Full Text] [Related]
20. [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences].
Kvitkina T; ten Haaf A; Reken S; McGauran N; Wieseler B
Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):528-38. PubMed ID: 25523852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
